Autopsy report · NCT07547436
A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis
Cause of deathFunding or business, also safety
“The pause is for strategic business reasons to facilitate internal portfolio review. The pause is not due to any concerns with patient safety, with program benefit/risk, or with trial integrity.”
Life of this trial
- Registered 2 months before it started.
- Suspended: paused, and may or may not restart.
- 70 participants planned (an estimate, not an actual count).
Vital statistics
- Status
- Suspended
- Phase
- Phase 2
- Sponsor
- Sanofi
- Sponsor type
- Industry
- Conditions
- Non-cystic Fibrosis Bronchiectasis
- Interventions
- SAR445399; Placebo
- Participants
- 70 (planned, not actual)
- Sites
- 4
- Countries
- United States
Trials that died the same way
- RCT of Mobile Apps & FitBit v. Usual Care
“Study is paused for interim analysis.” - Atacicept in Subjects With Active Lupus Nephritis (COMPASS)
“Study recruitment is paused due to business reasons, but not due to regulatory or safety concerns.” - Identifying the Neural Basis of Capability for Suicide
“Study is currently on pause until further funding is received to continue the project.” - Somatostatin Analogues With Perioperative Antibiotics Versus Prolonged Antibiotics
“study paused for interim analysis” - Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
“study was stopped for business/administrative reasons and not for patient safety concerns”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.